Vimta Labs Limited has informed the Exchange regarding a press release dated May 06, 2026, titled "Press Release - Audited Financial Results- Q4 and financial year ended 31st March 2026 ".
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vimta Labs reported its highest-ever quarterly revenue of Rs. 1,120 Mn in Q4 FY26, up 16.6% YoY. For the full year FY26, total income reached Rs. 4,163 Mn, a growth of 19.5% YoY driven by strong performance in Pharma and Food divisions. EBITDA for FY26 stood at Rs. 1,489 Mn (margin 35.8%), and PAT was Rs. 775 Mn (margin 18.6%). EPS for the year was Rs. 17.4. The company notes it sold its Diagnostic and Pathological services business to Thyrocare Technologies in October 2024, with prior period figures regrouped for comparability.
Strong top-line growth nearly at the 20% threshold demonstrates robust demand for Vimta's testing and research services. However, both EBITDA margin (35.8% vs 36.2% in FY25) and PAT margin (18.6% vs 19.2% in FY25) contracted slightly, indicating margin pressure despite volume growth. The continued margin compression and the divestment of the diagnostic business are worth monitoring for long-term profitability.